The FDA extended the review period for Exelixis's new drug application for zanzalintinib by three months, deeming updated safety and efficacy data a major amendment. While this caused an immediate stock dip, an analyst believes the risk of rejection remains low due to demonstrated overall survival benefits, suggesting the long-term revenue potential is not significantly diminished.
The FDA extended the review period for Exelixis's zanzalintinib NDA by three months, pushing the action date to March 3, 2027. This delay, triggered by updated safety and efficacy data submitted by Exelixis, led to an immediate decline in EXEL's stock price. While the short-term market reaction is negative due to uncertainty and delay, analysts like William Blair's Andy Hsieh believe the risk of outright rejection is low, citing positive Phase 3 trial results. The long-term revenue potential for zanzalintinib is not expected to be significantly impacted, but investors should anticipate increased short-term volatility.